Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders changes as well. A "one size fits all" approach can not be used because youth who have committed sexual crimes are a diverse population, meaning they are all different in numerous ways. Treatment response to sexual abuse by juveniles is based on relapsed prevention, offense cycle, and presumption of sexual dividends. Some research coming out suggests that the successful treatments are those which include community-based and involve supportive adults in the youth's life. Something to keep in mind is label the behavior of the youth, not their identity, because it helps to make sure that youths do not develop a